Inclusion Criteria:~* Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid
pathology.~* Have a reliable study partner and backup study partner familiar with overall function and
behavior, such as day-to-day activities and cognitive abilities.~* Have adequate literacy, vision, and hearing
for neuropsychological testing at screening.~* Have a Mini Mental Status Exam (MMSE) score consistent with no
to minimal cognitive impairment.~* Have a Functional Activities Questionnaire (FAQ) score consistent with no to
minimal functional impairment.~* If currently receiving medications as symptomatic treatment for AD, dose has
been stable for at least 30 days before screening.~
